FDA approves new drug application for Pliaglis

The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.

Related Videos
Related Content

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023

Breast Care for Pregnant and Lactating Patients

March 28th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Improve Patient Outcomes With Better Language Access

March 28th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

Self-Esteem in Males with Alopecia Improved by Hair Transplantation

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.